Exploring Regulatory Flexibility to Create Novel Incentives to Optimize Drug Discovery Provisionally Accepted
Jacqueline A. Sullivan
E Richard Gold- 1Western University, Canada
- 2McGill University, Canada
Efforts by governments, firms, and patients to deliver pioneering drugs for critical health needs face a challenge of diminishing efficiency in developing those medicines. While multi-sectoral collaborations involving firms, researchers, patients, and policymakers are widely recognized as crucial for countering this decline, existing incentives to engage in drug development predominantly target drug manufacturers and thereby do little to stimulate collaborative innovation. In this mini review, we consider the unexplored potential within pharmaceutical regulations to create novel incentives to encourage a diverse set of actors from the public and private spheres to engage in the kind of collaborative knowledge exchange requisite for fostering enhanced innovation in early drug development.
Keywords: collaboration, Drug Development, incentives, Open Science, Patents, regulatory exclusivity
Received: 31 Jan 2024;
Accepted: 17 Apr 2024.
Copyright: © 2024 Sullivan and Gold. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dr. Jacqueline A. Sullivan, Western University, London, N6A 3K7, Ontario, Canada
Dr. E Richard Gold, McGill University, Montreal, Canada